COVID-19: Vaccines and Therapeutics
Clinical leaders at the University of Utah Health are sharing data and stories to encourage people to get vaccinated or boosted against COVID-19. The health system also is the epicenter of Project Art Heals Utah, a collaborative art project that honors the “shared resilience” of communities during…
With the start of flu season, AHA is providing a new batch of Halloween- and autumn-themed resources for hospitals’ and health systems’ use to encourage influenza and COVID-19 vaccination. The October United Against the Flu toolkit includes downloadable plug-and-play social media assets,…
The Centers for Disease Control and Prevention today recommended Moderna’s bivalent COVID-19 vaccine booster for children aged 6-17 and Pfizer’s bivalent COVID-19 vaccine booster for children aged 5-11 after the Food and Drug Administration authorized them for these ages.
COVID-19 vaccinations are associated with over 650,000 fewer hospitalizations and 300,000 fewer deaths in the Medicare population through December 2021, saving an estimated $16 billion in direct medical costs, the Department of Health and Human Services reported today.
The COVID-19 vaccine is one of the most exciting developments in global health in recent history. What’s also exciting are key lessons from the national rollout of the vaccine and how this new knowledge gives us hope for a future of better health for all. In this episode, J
The COVID-19 monoclonal antibody therapy Evusheld may not prevent COVID-19 caused by certain variants of the virus, the FDA announced this week.
Increasing bivalent COVID-19 booster vaccinations this year to 2020-2021 flu vaccination rates could prevent an additional 75,000 deaths and 745,000 hospitalizations and avert $44 billion in medical costs over the next six months, researchers estimate in a Commonwealth Fund blog post.
Pfizer has submitted a request for the Food and Drug Administration to authorize a 10-microgram booster dose of its bivalent COVID-19 vaccine booster for emergency use in children aged 5-11.
Health care providers who treat uninsured or underinsured patients with commercially procured bebtelovimab, a COVID-19 monoclonal antibody therapy for outpatients at high risk for hospitalization, may be eligible for free replacement doses from the Department of Health and Human Services. HHS plans…
Moderna Friday submitted its request that the Food and Drug Administration authorize for emergency use its bivalent COVID-19 vaccine for children and adolescents between the ages of 12 and 17 years old. The bivalent version of its mRNA vaccine is designed to target both the original strain of SARS-…